Loading...
Chemours reported a 6% year-over-year increase in net sales to $1.8 billion for Q3 2022. Net income was $240 million, resulting in an EPS of $1.52. Adjusted EBITDA decreased by 2% year-over-year to $363 million. The APM and TSS segments delivered strong results, while the Titanium Technologies segment faced headwinds.
Net Sales increased by 6% year-over-year to $1.8 billion.
Net Income reached $240 million, with an EPS of $1.52.
Adjusted EBITDA was $363 million, a decrease of 2% year-over-year.
Free Cash Flow amounted to $229 million.
Chemours expects Adjusted EBITDA for FY 2022 to be between $1.40 billion and $1.45 billion and Free Cash Flow to be greater than $575 million.